148 related articles for article (PubMed ID: 29768028)
1. Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions.
Volpe DA; Balimane PV
Bioanalysis; 2018 May; 10(9):619-623. PubMed ID: 29768028
[No Abstract] [Full Text] [Related]
2. Transporter-mediated drug interactions: clinical implications and in vitro assessment.
Lin JH
Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):81-92. PubMed ID: 17269896
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters.
Sun P; Liu K
Curr Drug Metab; 2018; 19(13):1119-1129. PubMed ID: 30062958
[TBL] [Abstract][Full Text] [Related]
4. A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers.
Shen H
Bioanalysis; 2018 May; 10(9):625-631. PubMed ID: 29768022
[No Abstract] [Full Text] [Related]
5. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
6. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
7. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.
Lu C; Liao M; Cohen L; Xia CQ
Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292
[TBL] [Abstract][Full Text] [Related]
8. [Progress in regulation of drug transporters and metabolic enzymes by resveratrol].
Jia YM; Liu ZH; Liu KX
Yao Xue Xue Bao; 2016 Jun; 51(6):860-5. PubMed ID: 29878738
[TBL] [Abstract][Full Text] [Related]
9. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
10. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance?
Chen F; Li DY; Zhang B; Sun JY; Sun F; Ji X; Qiu JC; Parker RB; Laizure SC; Xu J
Drug Metab Rev; 2018 Aug; 50(3):369-397. PubMed ID: 30221555
[TBL] [Abstract][Full Text] [Related]
11. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
12. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Mogalian E; German P; Kearney BP; Yang CY; Brainard D; McNally J; Moorehead L; Mathias A
Clin Pharmacokinet; 2016 May; 55(5):605-13. PubMed ID: 26519191
[TBL] [Abstract][Full Text] [Related]
13. Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates.
Weiß F; Hammer HS; Klein K; Planatscher H; Zanger UM; Norén A; Wegler C; Artursson P; Joos TO; Poetz O
Drug Metab Dispos; 2018 Apr; 46(4):387-396. PubMed ID: 29343608
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Zhang H; Cui D; Wang B; Han YH; Balimane P; Yang Z; Sinz M; Rodrigues AD
Clin Pharmacokinet; 2007; 46(2):133-57. PubMed ID: 17253885
[TBL] [Abstract][Full Text] [Related]
15. Transporter-mediated drug-drug interactions.
Zhang L; Huang SM; Lesko LJ
Clin Pharmacol Ther; 2011 Apr; 89(4):481-4. PubMed ID: 21423238
[TBL] [Abstract][Full Text] [Related]
16. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications.
Scheer N; Wolf CR
Xenobiotica; 2014 Jan; 44(2):96-108. PubMed ID: 23845026
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes.
Elbarbry FA; Marfleet T; Shoker AS
Transplantation; 2008 May; 85(9):1222-9. PubMed ID: 18475175
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
19.
Säll C; Fogt Hjorth C
Xenobiotica; 2022 Jan; 52(1):1-15. PubMed ID: 34913834
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of pharmacokinetic drug-drug interactions].
Levêque D; Lemachatti J; Nivoix Y; Coliat P; Santucci R; Ubeaud-Séquier G; Beretz L; Vinzio S
Rev Med Interne; 2010 Feb; 31(2):170-9. PubMed ID: 19740579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
